Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Matrixx v. Zila

This article was originally published in The Tan Sheet

Executive Summary

Matrixx Initiatives' request for temporary restraining order against Zila Pharmaceuticals Swab Technologies has been denied, Zila announces April 23. Phoenix, Ariz.-based firm says Matrixx' claims Zila breached a swab-manufacturing contract by failing to produce requested levels of swabs and raising swab prices "are wholly without merit." Zila intends "to vigorously defend these actions," has filed motion to dismiss remainder of case. Matrixx filed claim April 4 in Arizona state court, seeking temporary restraining order and monetary damages...

You may also be interested in...

Matrixx, Zila settlement

Zila's existing swab supply agreement with Matrixx extended 90 days to March 31, 2004 under a litigation settlement announced Aug. 14. However, "it is unlikely that the contract will be renewed at that time," Zila says. Under the pact, Matrixx accepted Zila's current production level and swab price increases, Zila says. Matrixx, which markets Zicam Cold Remedy Swabs, filed suit in Arizona state court in April, alleging that Zila breached its supply contract by not producing agreed-upon levels of swabs and raising prices (1"The Tan Sheet" April 28, 2003, In Brief)...

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts